A new JAAD commentary disputes a 2026 case-control study meant to validate PIRME, a checkpoint-inhibitor rash first named by the same research group in a 2020 case series with no control arm.
A new JAAD commentary disputes a 2026 case-control study meant to validate PIRME, a checkpoint-inhibitor rash first named by the same research group in a 2020 case series with no control arm.
A second round of published disagreement has hit a JAAD skin cancer imaging study within three months, and the specific objections in the October 14, 2026 exchange remain locked behind a paywall.
A new JID paper, online since October 14, 2026, argues diagnostic definitions reshape atopic dermatitis GWAS results; its full text is paywalled, but prior studies already show a 59-definition spread and a 26.7% sensitivity gap behind that claim.
A JAAD paper posted online October 12, 2026 promises to reframe sunscreen absorption trials after bemotrizinol's FDA approval, but its full text is paywalled and unverifiable beyond the title and byline.
A new JAAD commentary names the conflict of interest facing clinicians who prescribe GLP-1 weight-loss drugs and then sell the fillers that treat the facial volume loss those drugs can cause.
A JAAD letter responds to a Lilly hidradenitis suppurativa trial whose primary endpoint missed significance (P=.19) but whose headline 99.9 percent figure came from a Bayesian analysis borrowing historical, not randomized, placebo data.
A new JAAD paper on drug-induced subacute cutaneous lupus posted October 5, 2026, but the condition it studies still has no formal diagnostic criteria separating it from idiopathic disease.
A systematic review posted October 5, 2026 in the Journal of Investigative Dermatology promises to assess AI tools for diagnosing and scoring vitiligo, but the vitiligo-AI literature it builds on has never reported how these tools perform across skin tones.
A new JAAD commentary questions what dupilumab "real-world persistence" studies actually prove, after surveys from Italy, Spain, Portugal, Canada and the US produced survival rates ranging from 54 to 90 percent.
A reply letter in JAAD challenges a Danish registry study's claim that bimekizumab beats brodalumab on 2-year drug survival, pointing to thin follow-up data and an unaddressed REMS confound.
JAAD posted a reply from the original authors on October 5, 2026, closing a three-letter exchange over a Danish study that credited bimekizumab with a 26-point drug-survival edge over brodalumab.
A dsm-firmenich-authored paper in the Journal of Investigative Dermatology claims the first absolute-density 3D map of facial skin microbes, but a 2022 study already mapped the face in 3D, and the new paper's commercial framing outruns what its single mapped cohort can show.
A new Journal of Investigative Dermatology paper proposes 3D imaging to grade sun-damaged skin, but its own proof-of-concept label, and the field's history of validating tools against older photos rather than tissue damage, limits what it can claim.
A JAAD comment on a 108-patient retrospective review of JAK inhibitor switching in alopecia areata asks whether "improvement after switching" reflects a true drug effect or just delayed response and natural relapse cycles the study design cannot separate out.
A new JAAD real-world study on abrocitinib in elderly atopic dermatitis patients flags "appetite changes" as an outcome, but its full text is paywalled and no prior abrocitinib literature tracks appetite at all.
A Journal of Investigative Dermatology paper on hydrogel drug delivery is still paywalled, but the preclinical literature it joins shows a pattern worth checking before calling anything a breakthrough.
A Journal of Investigative Dermatology paper describes a cell-based light sensor for UVA exposure. Its scope is a lab readout, not the regulatory validation that would let it replace human testing.
A new Journal of Investigative Dermatology study finds sun-damaged skin's circadian clock runs weaker and earlier than protected skin, but it was co-funded by a skincare brand now marketing a night serum on the back of it.
A pediatric trial label can conceal a wide evidence gap: adolescents have an approved systemic alopecia areata drug, while younger children await efficacy data.
A mouse experiment suggests that one itch-linked nerve class restrains psoriasis-like inflammation while another fuels it. The finding is preventive, acute and untested in people.
A new cross-trait GWAS in the Journal of Investigative Dermatology links acne and IBD through shared risk genes, but germline data can't adjudicate whether a drug like isotretinoin causes bowel disease.
A paper slated for the October 2026 Journal of Investigative Dermatology compares itch scales against cytokine levels in atopic dermatitis, testing a measurement gap that has quietly shaped drug-trial endpoints for years.
A paired-biopsy study of nine Korean donors finds senescent keratinocytes, not just dermal fibroblasts, driving facial senile lentigo. The evidence spans tissue staining and a co-culture test, but a small, ethnically narrow sample limits how far the mechanism can be generalized.
A JAAD rebuttal letter answers a critique of Incyte's ruxolitinib cream trial for hidradenitis suppurativa, but the exchange reveals more about a buried pain outcome than it resolves.
A new JID paper on the SD-ACNE acne trial is not a results readout; it is a methods and ethics report on how participants learned their drug assignment after the double-blind phase ended.
A new JAAD letter argues the 2019 psoriasis biologics monitoring guideline has gaps for newer drugs, but it is itself a short commentary, not an original study with new patient data.
A JAAD letter challenges a phase 2 ruxolitinib cream trial for treating pain as a footnote when vehicle cream matched the drug on pain relief, and the industry-linked rebuttal doesn't resolve whether a 69-person study was ever powered to test that claim.
A June 2026 JAAD commentary argues a Boston-led cohort study on multidisciplinary cSCC care fell for immortal time bias, kicking off a four-paper chain testing what one retrospective design can actually prove.
COSRX The Alpha-Arbutin 2 Discoloration Care Serum combines 2% alpha-arbutin with tranexamic acid 3%, niacinamide 5% and NAG 2%, backed by 2024 P&K clinical, non-comedogenic and sensitive-skin irritation reports.
A single-author JAAD paper proposes adding mupirocin 2% ointment to treatment options for Zoon balanitis, but its case-report format can show plausibility, not superiority over existing therapies.
A JAAD letter by Pagliarello and Girardelli challenges a retrospective cohort study on baricitinib and prior steroid use in alopecia areata, exposing what retrospective data can and cannot prove.
A new JAAD analysis finds patients on GLP-1 receptor agonists start fewer HS biologics, but the study cannot separate genuine disease improvement from unequal access to prescribing.
A new analysis in the Journal of the American Academy of Dermatology finds electronic health record studies matched established evidence about 80% of the time, but the gap tells its own story.
A SKH1 hairless mouse trial found dietary Polypodium leucotomos extract barely changed acute UV skin reactions and did not slow chronic UV-driven skin tumor formation.
A October 2026 JAAD paper on hormone therapy and skin aging lands amid a regulatory reversal, but the underlying trial evidence for cosmetic benefits remains thin.
A JAAD paper titled simply "Herpes zoster" went live on ScienceDirect Sept. 16, 2026, tagged "available online" ahead of formal issue assignment, with no abstract yet public.
A new JAAD paper touts ixekizumab's "treat-to-target" success at 5 years, but the data is a post-hoc reframing of a 2020-published UNCOVER-3 readout, not a new trial.
A West China Hospital team's new JAAD reply defends a disputed finding: hemangioma ulceration under propranolol starts nearly two months later than untreated ulceration, but the underlying Comment and rebuttal remain unindexed and unretrieved.
A Mendelian randomization study in the Journal of Investigative Dermatology finds genetically predicted GLP1R expression raises male pattern hair loss risk, a modest statistical link that stops well short of proving Ozempic causes baldness.
A new dermatology review finds acne trials still under-report Hispanic/Latino enrollment, a gap that predates and outlasts several federal diversity mandates.
A JAAD study extending SEER surveillance through 2022 confirms rising CTCL incidence, but two decades of registry data still can't say why rates keep climbing.
A JAAD-bound study ties high circulating MRGPRX2 to antihistamine failure in chronic urticaria, but a 2025 Scientific Reports paper on the same receptor found the opposite.
A September 2026 JAAD paper proposes T-cells as a biomarker for female pattern hair loss, a claim that sits uneasily against 2015 histology using the same cells to diagnose alopecia areata instead.
A JAAD commentary published online September 7, 2026, raises ethical questions about "prejuvenation," but the term itself splits between cosmetic dermatology and experimental cell reprogramming.
A September 7, 2026 JAAD reply to a comment on a niacinamide-heart-risk TriNetX study lands inside a wider 2026 reckoning over sloppy, AI-assisted TriNetX research methodology.
A new JAAD paper on mechlorethamine gel prescribing draws on Medicare data whose own reporting threshold hides most low-volume prescribers, making its headline "44 specialists" figure a floor, not a ceiling.
A post hoc analysis in the Journal of Investigative Dermatology ties deucravacitinib to lower inflammatory biomarkers in psoriasis patients, but the underlying trials weren't built to test cardiovascular outcomes.
A Journal of Investigative Dermatology study finds high-dose NB-UVB drives fibroblast senescence and vitiligo progression, while low doses calm immune attack; the doses tested, not clinical practice, are what's actually new here.
A September 2026 Journal of Investigative Dermatology review synthesizes prior mouse and cell studies showing neutrophil traps aid S. aureus in damaged skin, evidence that stays mostly preclinical.
A six-day combo of two old generic drugs, vitamin D analog calcipotriene and chemo agent 5-fluorouracil, cut skin cancer recurrence fourfold in a 3-year study, and is now being tested in transplant patients.
A new JID paper claims fibroblast collapse drives skin aging "in vivo," but the underlying mechanism was first proposed in 2008 and tested mostly in culture and mice until now.
A conference Q&A urging dermatology clinicians to embrace immunologic pathways and push harder for pediatric biologics glosses over how narrow FDA-approved options for children actually are, and how much the message doubles as promotion for the sponsoring conference.
Conexeu Sciences is betting that rebuilding skin's collagen scaffold, not just adding volume, is the next frontier in aesthetics, and that GLP-1 drugs just created the patient population to prove it.
A JAAD comment challenges a Mayo Clinic cohort study that found isotretinoin doesn't shorten teens' final height, pointing instead to the slowed growth velocity the study measured along the way.
Clear Health markets Isoclear as the first prescription topical isotretinoin system available in the United States, but its own product page discloses that the clinical evidence behind it comes from the ingredient generally, including products once sold abroad, not from trials of this specific formulation.
The Journal of Investigative Dermatology's August 2026 issue carries a two-page Letters to the Editor essay, not a study, in which two dermatologists and an artist read Xu Beihong's 1930s ink painting Eight Horses as an argument for training clinicians to look closely; it cites no data for that claim.
A new preclinical study of a Psorospermum febrifugum bark-extract cream reports lipase inhibition, sebum reduction, and dermal safety in rats, but never tests the finished cream against Cutibacterium acnes, the bacterium the condition is named for.
A new ex vivo study finds that FLCN, the gene mutated in Birt-Hogg-Dube syndrome, suppresses hair follicle growth in organ-cultured human follicles, but the syndrome it causes in real skin builds disorganized follicular growths, not fuller hair.
An August review suggests UPF labeling for adhesive sun patches, but current AATCC and ASTM standards address textile fabrics and products. The supporting SPF 100 result came from instrument testing of an experimental material, leaving retail patches without a clean comparison to sunscreen or clothing labels.
A new JAMA Dermatology viewpoint argues most isotretinoin patients don't need routine liver and lipid testing, but the drug's FDA-approved label never actually specified the monthly schedule that became dermatology's default. That habit was built by clinical culture over three decades, not by regulation, and it is the fourth step in a ten-year sequence of evidence pulling practice back toward what the label always allowed.
Itching with no visible rash has a documented but narrow link to cancer, strongest in Hodgkin lymphoma, where it can appear years before diagnosis yet doesn't track with tumor size. The biology behind it is still unresolved, and most unexplained itch traces back to something else entirely.
No trial has ever tested the new oral psoriasis drug icotrokinra against injectable IL-23 inhibitors head to head, and the indirect comparisons published so far, including two tied to the drugmakers involved, disagree with each other.
A new light-scattering method for catching early emulsion breakdown, built to spot phase separation and freeze damage before they're visible, comes from the quality-control lab of one of the world's largest cosmetics contract manufacturers, whose factories make face masks and skincare sold under hundreds of other companies' names.
A new review of antimicrobial peptides in skin cancer names LTX-315 as a clinical candidate, but the compound is a synthetic redesign of a cow's-milk peptide, not a skin peptide, and it had already been renamed ruxotemitide and moved through two Phase II melanoma trials by the time the review reached print.
A 40-patient Phase 2 trial of the topical gel TolaSure for epidermolysis bullosa simplex is nearing an interim data check, but the predecessor study its confidence rests on enrolled six adults instead of the ten planned and still has no results posted on ClinicalTrials.gov more than three years after it ended.
A short communication published August 10 in the Journal of Investigative Dermatology reports a generative method for narrowing Fitzpatrick skin-tone disparities in AI skin-tumor classification; PubMed's affiliation records show the nine-person team spans hospitals in Seoul, the Philippines, and Ethiopia, a detail the paper's public summary leaves out.
A new retrospective study on predictors of systemic treatment response in pediatric alopecia areata went online this month with no public abstract yet, but the treatment landscape it examines is checkable now: only one systemic drug is FDA-approved for children with the condition, and only for ages twelve and up.
A formal exchange in a major dermatology journal shows specialists still disagree about routinely testing for gut inflammation before starting bimekizumab for hidradenitis suppurativa, and the reply's byline mixes independent academics with employees of the drug's manufacturer.
A search of the public archive of U.S. appellate opinions turns up only two published cases that ever use the clinical term delusional parasitosis, and in neither one is the diagnosis itself what the court had to decide.
liomys